GENSCRIPT-BIOTECH
GenScript Biotech (Netherlands) BV , a subsidiary of GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), a world-leading biotechnology company, and IES Diagnostics, the Life Science division of IES Medical, a company based in Spain, announced they have signed an agreement for the exclusive distribution of the GenScript cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit in Spain, Portugal, and Andorra.
The test measures the presence of neutralizing antibodies (NAbs) in patients recovering from COVID-19 or receiving a vaccine. It is the only U.S. FDA Emergency Use Authorized (EUA) serology test for neutralizing antibodies from recent and prior SARS-CoV-2 infections. The kit is also CE marked (Europe) and has received HSA provisional approval (Singapore), ANVISA in Brazil, ANMAT in Argentina and has recently received clearance from the Ministry of Health and Prevention (MOHAP) in the United Arab Emirates as a medical device.
"With this collaboration, IES Diagnostics and GenScript will join forces to serve the local community with our expertise and resources. Since the outbreak of the worldwide pandemic in 2020, our company has been committed to supporting the global community in fighting COVID-19 with a comprehensive portfolio to support therapeutics and vaccine research and development, and diagnostic tool development including the novel cPass kit," said Aaron Qian, the President of European Division of GenScript.
Hubert Thomassen, CEO of IES Medical, said, "We are honored to be working with GenScript, proud to provide the unique and highly innovative cPass kit to our society that will contribute decisively to the knowledge of the immune status and level of protection of both those who have suffered a SARS-CoV-2 infection and those citizens who have been or will be vaccinated. The cPass kit is an essential tool in the development of any therapy aimed at combating this pandemic and in the development of an international immunity passport that allows our society to resume a normal social and economic life."
About GenScript Biotech Corporation
GenScript Biotech Corporation (Stock Code: 1548.HK) is a global biotechnology group. Based on its leading gene synthesis technology, GenScript has developed four major platforms including the global cell therapy platform, the biologics contract development and manufacturing organization (CDMO) platform, the contract research organization (CRO) platform, and the industrial synthesis product platform. The company’s operations span over 100 countries and regions worldwide with legal entities located in the US, Mainland China, Hong Kong, China, Japan, Singapore, the Netherlands, and Ireland. GenScript provides premium, convenient, and reliable products, and services for over 100,000 customers.
For more information visit http://www.genscript.com .
About IES Diagnostics
IES Diagnostics is the LifeScience division of IES Medical. IES Medical has its headquarters in Bilbao and offices in Madrid and Barcelona. The company directly serves clients all over the Iberian peninsula. IES Medical has a long-standing reputation for providing innovative products that contribute to improving the health of society in the areas of Emergency Medicine, Woundcare, Respiratory, and Diagnostics. The overall objective of IES Medical is to provide innovation for better care,
For more information visit https://www.iesmedical.es/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413006175/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hamad International Airport's Senior Operations Manager appointed as CEO of Ancona International Airport14.10.2025 09:00:00 CEST | Press release
Ancona International Airport (“AIA”), a Njord Partners portfolio company, is pleased to announce the appointment of Giorgio Buffa as its new Chief Executive Officer, effective 13 October 2025. Giorgio Buffa joins Ancona from Doha’s Hamad International Airport, where he was the Senior Operations Manager. He brings over 20 years of dedicated experience in the airport and airline industries, having spent his entire career in aviation. He is recognised for driving operational excellence and pioneering sustainable development at Hamad International Airport, which has, for multiple years, been named the "World's Best Airport" by Skytrax, setting new standards in the airport sector. For the past nine years, he has been instrumental in overseeing key operational functions and successfully navigated the COVID-19 period as well as major events such as the FIFA World Cup. Formerly a pilot with Alitalia and Air One, Giorgio has held various senior leadership roles in airport operations, including
PPG introduces PPG MIX‘N’SHAKE automated stirring technology for body shops14.10.2025 08:30:00 CEST | Press release
System improves productivity, reduces waste, enhances color accuracy PPG (NYSE: PPG) today announced the introduction of PPG MIX‘N’SHAKE™ automated stirring technology designed to eliminate traditional manual stirring methods in the automotive refinish industry. The system, which is available globally, improves paint mix consistency, reduces consumable waste and saves time for painters and body shops. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013065453/en/ PPG MIX’N’SHAKE™ automated stirring technology replaces manual stirring processes to ensure a homogenized paint mix, complete color accuracy, and a better workplace. The PPG Mix‘n’Shake system will debut at the EQUIP AUTO trade show in Paris taking place Oct. 14-18. PPG will also showcase its PPG LINQ™ digital ecosystem, which is a finalist for the prestigious EQUIP AUTO Innovation Award. Because the PPG Mix‘n’Shake system eliminates manual stirring, it ensures con
Glesys to Acquire Verne’s Managed Private Cloud Operations and Two Data Centers in Finland14.10.2025 08:00:00 CEST | Press release
Verne, the leading provider of low-carbon high-performance data centers across the Nordics, has today announced that Glesys, a leading Nordic provider of cloud and IaaS services, will acquire Verne’s managed private cloud operations in Finland, including data center facilities in Pori and Tampere. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251006898290/en/ Pori Data Center Tunnel Corridor The agreement reflects both companies’ strategic priorities: for Glesys, it represents an important step in expanding its cloud and IaaS services, strengthening its position as a market leader in the Nordics and enhancing its capacity to deliver secure, energy-efficient and scalable solutions in the region. For Verne, it supports a sharpened focus on delivering low-carbon, high-performance colocation for AI and enterprise workloads, including its expansion plans in Mäntsälä, announced earlier this year. Glesys and Verne will continue to
Avanzanite Expands Italian Operations with General Manager Appointment14.10.2025 07:30:00 CEST | Press release
Giovanni Galliano joins Avanzanite having led 12 orphan medicine launches in Italy and overseen operations with more than €100 million in annual revenue. Avanzanite initiates engagement with the Italian rare blood disorder community who include the largest number of thalassemia patients in Europe. Avanzanite’s Q3 2025 revenues are 20% higher than Q2 2025, marking the strongest quarter to date. Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, announced today the appointment of Giovanni Galliano as General Manager for Italy. As the seventh executive leadership hire in 2025, this appointment further strengthens Avanzanite’s “Champions League” team of now more than 60 pharma professionals, while expanding operations into the European Union's third-largest economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013986565/en/ Giovanni Galliano, th
The Estée Lauder Companies Opens Global Fragrance Atelier in Paris, Accelerating Next-Generation Innovation in Perfume Artistry14.10.2025 07:00:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE:EL), under the High Patronage of Mr. Emmanuel Macron, President of the French Republic,today announced the opening of its Fragrance Atelier within its new La Maison des Parfums on Rue Volney in Paris. This newly established global innovation hub is fully dedicated to world-class fragrance expertise, advanced technologies and cutting-edge capabilities, and will accelerate the company’s strategic ambitions in luxury and prestige fragrances. Rooted in the legacy of Mrs. Estée Lauder’s pioneering vision and her lifelong passion for fragrance, the Atelier’s opening marks a significant milestone in the company’s longstanding commitment to fragrance excellence and craftsmanship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013447078/en/ The Exterior of La Maison des Parfums “It is with great pride and excitement that we open our Fragrance Atelier in Paris,” said Stéphane de La Faverie, Pre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom